Skip to content
Screener

Charles River Laboratories CRL Common stock, par value (in dollars per share)

Common stock, par value (in dollars per share) at other companies

Ginkgo Bioworks logo
Ginkgo BioworksDNA
$00.0%
Revvity logo
RevvityRVTY
$10.0%
Fortrea Holdings Inc. logo
Fortrea Holdings Inc.FTRE
IQVIA logo
IQVIAIQV
NeoGenomics logo
NeoGenomicsNEO
Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO

Other financials

Income statement

See full
Revenue$1.0B-2.7%
Gross profit$349.0M-3.5%
Operating income$119.9M+19.7%
Net income-$1.5M-103%
EPS (diluted)-$0.03-103%

Balance sheet

See full
Cash & equivalents$240.6M+30.2%
Total debt$3.0B+8.1%
Total equity$2.8B-15.3%
Total assets$7.5B-0.4%

Cash flow

See full
Operating cash flow$179.7M-12.2%
CapEx$31.1M-11.9%
Free cash flow$148.6M-12.2%

Valuation

See full
Market cap$12.77B+74.2%
Enterprise value$15.57B+56.4%
P/S3.2×+1.4×

Profitability

See full
Gross margin84.7%
Operating margin13%-2.4pp
Net margin-6%
FCF margin9.3%-5.1pp

Returns & leverage

See full
Return on equity-7.7%
Debt / equity1.1×+0.2×
Current ratio1.3×0.0×

Where this comes from

Reported directly by Charles River Laboratories in its filing.

Tagged under the XBRL concept us-gaap:CommonStockParOrStatedValuePerShare.

The source filing: Charles River Laboratories’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 9:21 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001100682-26-000118
Line itemJune 27, 2026December 27, 2025
Redeemable noncontrolling interests42,53741,263
Equity:
Preferred stock, $0.01 par value; 20,000 shares authorized; no shares issued and outstanding
Common stock, $0.01 par value; 120,000 shares authorized; 49,550 shares issued and 47,728 shares outstanding as of June 27, 2026, and 49,217 shares issued and outstanding as of December 27, 2025496492
Additional paid-in capital1,986,0231,947,301
Retained earnings1,372,2951,388,620
Treasury stock, at cost, 1,822 and zero shares, as of June 27, 2026 and December 27, 2025, respectively(323,189)
Accumulated other comprehensive loss(195,989)(171,783)

Item 1. Financial Statements

FAQ

What is Charles River Laboratories's common stock, par value (in dollars per share)?
Charles River Laboratories (CRL) reported common stock, par value (in dollars per share) of $0.01 in Q2 2026.
How has Charles River Laboratories's common stock, par value (in dollars per share) changed year-over-year?
Charles River Laboratories's common stock, par value (in dollars per share) decreased by 0.0% year-over-year, from $0.01 to $0.01.
What is the long-term trend for Charles River Laboratories's common stock, par value (in dollars per share)?
Over 5 years (2020 to 2025), Charles River Laboratories's common stock, par value (in dollars per share) has grown at a 0.0% compound annual growth rate (CAGR), from $0.01 to $0.01.
What does common stock, par value (in dollars per share) mean?
Common stock, par value (in dollars per share)

Ask your AI about Charles River Laboratories's common stock, par value (in dollars per share).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude